Skip to main navigation
HomeContact Us
×
 
About Us
About Us
About Alkermes
Our CompanyMessage From the CEOLocations
Leadership
Management TeamBoard of Directors
Collaborations
Strategic Partners
Products
Products
Products
Products Overview
United States
ARISTADA ® VIVITROL ®Proprietary Products and TechnologiesWholesaler and Purchasing Information
European Union
EU Products Using Alkermes Technologies
Research & Development
Research & Development
Research & Development
R&D OverviewOur R&D ApproachPipelineTechnology PlatformsManufacturing
Other Information
Clinical TrialsExpanded Access
Responsibility
Responsibility
Responsibility
Corporate Responsibility Corporate Giving and Funding Alkermes Inspiration Grants® COVID-19 Relief Fund Medical Education Grants Alkermes Pathways Research Awards® Investigator Sponsored Studies Public Policy
Investors
Investors
Investors
Corporate Overview Press Releases Investor Events Stock Information SEC Filings Annual Reports
Financials
Snapshot Trading Statistics
Other Information
Email Alerts
News & Events
News & Events
News & Events
Press ReleasesMedia Kit
Careers
Careers
Careers
Working TogetherOur Core ValuesTotal RewardsMeet Our EmployeesRecruiting AgenciesEqual Opportunity EmployerJobs Overview
Job Opportunities
Field Sales RolesAll Available Roles

Investors

Home Investors Snapshot

Investors

Corporate Overview Press Releases Investor Events Stock Information SEC Filings Annual Reports

Financials

Snapshot Trading Statistics

Other Information

Email Alerts

Snapshot

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Snapshot

Revenue & Earnings
Revenue (FY) $1,170.95
EBIT (Mil) (FY) $-162.08
EBIT (Mil) (MRQ) $-10.67
EBIT (Mil) (TTM) $-78.23
EBITDA (Mil) (FY) $-81.62
EBITDA (Mil) (MRQ) $9.91
EBITDA (Mil) (TTM) $3.81
Net Income Excluding Extraordinary Items (Mil) (FY) $-196.62
Net Income Including Extraordinary Items (Mil) (FY) $-196.62
Diluted EPS Excluding Extraordinary Items (FY) $-1.25
Diluted EPS Including Extraordinary Items (FY) $-1.25
Dividends
Yield (%) --
Dividend Record Date
Dividend Rate --%
Ratios
Price to Revenue (TTM) $2.99
Price to Revenue (MRQ) $3.29
Price to Revenue (FY) $2.99
Price To Cash Flow (TTM) $413.67
Price to Cash Flow (MRQ) $42.70
Price to Cash Flow (FY) --
Price to Book (MRQ) $3.23
Price to Book (FY) $3.20
Total Debt to Equity (MRQ) (%) 25.41%
Total Debt to Equity (FY) (%) 25.53%
Current Ratio (MRQ) $2.71
Current Ratio (FY) $2.46
Growth
5-Year Annual Dividend Growth Rate (%) --%
5-Year Annual Revenue Growth Rate (%) 13.61%

FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.

Copyright Refinitiv

Contact UsTerms of UsePrivacy PolicySitemap
Follow Us:
©2021 Alkermes. All Rights Reserved